




The relative strengths and weaknesses of Barinthus Biotherapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Barinthus Biotherapeutics plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 125% points. The greatest weakness of Barinthus Biotherapeutics plc is the variable Other Revenues, reducing the Economic Capital Ratio by 7.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 324%, being 109% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	125,742
Cost of Goods Sold	0
Intangible Assets	21,947
Liabilities, Current	15,657
Liabilities, Non-Current	11,447
Other Assets	5,265
Other Compr. Net Income	-2,444
Other Expenses	12,165
Other Liabilities	3,088
Other Net Income	6,743
Other Revenues	16,145
Property and Equipment	7,373
Research and Development	42,236
Selling, General and Administrative Expense	29,670

Output Variable	Value in 1000 USD
Assets	160,327
Liabilities	30,192
Expenses	84,071
Revenues	16,145
Stockholders Equity	130,135
Net Income	-61,183
Comprehensive Net Income	-62,405
BaseVar	149,961
ECR before LimitedLiability	232%
Economic Capital Ratio	324%